Biotechnology
exalt
exalt® develops a single-cell functional precision medicine diagnostic test to generate a personalized “Clear-my-Cancer” report, using a proprietary high-throughput technology.
​​​​​Application
​​​
Our technology identifies personalized cancer treatment recommendations by conducting a comprehensive screening of over 100 anti-cancer drugs (all approved within the European Union) on patient-specific viable cancer biopsies.
​
This single-cell functional precision medicine scFPM diagnostic procedure allows monitoring of treatment effectiveness ex vivo at single-cell level. Through the selective elimination of cancer cells in individual patients from our screening process, we identify the most effective treatment and provide a tailored clinical recommendation for each patient. ​​​​​
Perspective
​
Our approach has been clinically tested in a prospective study on 56 patients and is currently being evaluated in a randomized clinical trial including 150 patients with results expected in 2025.
​​Benefit​
​
In our initial clinical study using scFPM, our team recently demonstrated that scFPM offers significant clinical benefits to 54% of patients with aggressive, advanced-stage blood cancers, with 40% showing exceptional responses. Our technology allows for precise treatment matching and rapid turnover, specifically targeting cancer cells while sparing healthy ones, thereby minimizing the side effects of the selected treatments.
